Accutane (Isotretinoin) Manufacturing, Supply & Shortage History

Is Accutane still manufactured?

The branded U.S. product Accutane is not currently marketed. That does not mean isotretinoin disappeared. “Accutane” remains a widely used informal name for the molecule, but FDA's current isotretinoin information lists marketed products including Absorica, Absorica LD, Claravis, Amnesteem, Myorisan, and Zenatane 1.

DailyMed—the National Library of Medicine's repository for FDA-submitted labeling—also shows active generic isotretinoin labels. For example, a Zydus Pharmaceuticals label effective July 8, 2026 lists 10 mg, 20 mg, 30 mg, and 40 mg capsules 2.

The distinction is simple:

• Accutane is a discontinued brand in the U.S.
• Isotretinoin is the active ingredient and remains marketed.
• Brand and generic products are not necessarily identical in every formulation detail. A pharmacist or prescriber should confirm whether a proposed substitution matches the prescription and clinical plan.

Is there a U.S. isotretinoin shortage right now?

On August 29, 2026, a search of FDA's drug-shortage dataset returned no isotretinoin record. FDA updates its shortage list daily, and the answer can change; the FDA Drug Shortages database is the appropriate source to recheck 3.

No national listing does not guarantee that every strength and manufacturer is available at every pharmacy. FDA explains that a temporary or localized stock problem may occur even when a medicine is not in the national shortage database. Wholesaler inventory, a pharmacy's usual supplier, regional demand, and the exact strength can all affect a specific fill.

Unsupported historical percentages and claims of a continuous multiyear U.S. shortage should not be repeated as fact. We did not find authoritative evidence for that narrative.

Why an isotretinoin prescription can be delayed without a shortage

The pharmacy may not stock every product

Isotretinoin is distributed in multiple strengths and packages. A pharmacy can be out of one manufacturer's 40 mg capsule while another product or strength remains available through a different wholesaler. That is a product-level availability problem, not necessarily a national shortage.

Insurance may prefer a particular labeler or brand

A plan may cover one generic labeler, require prior authorization for a brand, or treat Absorica formulations differently from conventional isotretinoin capsules. A covered product can therefore be unavailable at one pharmacy even while other isotretinoin products are on the shelf.

iPLEDGE creates a separate dispensing gate

All FDA-approved isotretinoin products participate in the shared iPLEDGE REMS. The system is designed to mitigate embryo-fetal toxicity and requires coordinated actions by patients, prescribers, and pharmacies 4.

A pharmacy may possess the medication but be unable to dispense it until the applicable iPLEDGE requirements are satisfied. That is an access interruption, but it is not a manufacturing shortage.

FDA announced in June 2026 that planned iPLEDGE modifications were moved from August 8 to November 15, 2026 to allow more testing and reduce technical disruptions. Until implementation, FDA said the existing enforcement-discretion policy for pregnancy-testing requirements would continue 4.

A documented U.S. timeline

1982: FDA approval of Accutane

FDA's historical materials date the U.S. approval of Accutane to 1982. The medicine's teratogenicity was known during development, and pregnancy-prevention requirements evolved over subsequent decades 5.

1984: early dose-response evidence

A multicenter double-blind trial enrolled 150 people with treatment-resistant nodulocystic acne and compared three daily doses. All groups improved, while retreatment was more common in the lowest-dose group 6. This study helps explain isotretinoin's clinical history; it does not describe manufacturing capacity or a shortage.

2005–2010: iPLEDGE implementation and REMS approval

FDA says the iPLEDGE program was originally implemented in early 2005 and approved as a REMS in 2010. It is a shared system covering all FDA-approved isotretinoin products 4.

Current market: former brand, multiple active products

FDA now describes Accutane as not currently marketed in the U.S. while listing six marketed isotretinoin brand names. Current DailyMed records show additional active generic labels and package codes 1 2.

How to verify a suspected shortage

Use this sequence before concluding that isotretinoin is nationally unavailable:

1. Ask what is unavailable. Record the strength, quantity, brand or labeler, and whether the issue is pharmacy stock or wholesaler backorder.
2. Check the FDA database. Search the generic name “isotretinoin” in the Drug Shortages database.
3. Separate supply from authorization. Confirm whether insurance approval or iPLEDGE eligibility is the actual block.
4. Ask the pharmacist about obtainable equivalents. The pharmacist can see wholesaler inventory and determine whether the prescription permits substitution.
5. Contact the prescriber before changing strength or formulation. Do not combine capsules, change products, or interrupt treatment without instructions.

What patients should do when a fill is delayed

Call the dispensing pharmacy early enough to identify a stock problem before the iPLEDGE dispensing window becomes an issue. Ask the pharmacy to state the exact reason the claim cannot be completed: out of stock, wholesaler backorder, insurance rejection, prior authorization, prescription mismatch, or iPLEDGE status.

If a transfer or substitution is proposed, coordinate the pharmacy and prescriber rather than trying to purchase isotretinoin outside the regulated system. FDA specifically warns that buying isotretinoin online can bypass safeguards intended to prevent pregnancy exposure and other harms 1.